Development and Blood Compatibility of a Stable and Bioactive Metal–Organic Framework Composite Coating for Blood-Circulation Tubing
- 1 July 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 8 (8) , 3438-3449
Abstract
Medical devices that require substantial contact between blood and a foreign surface would be dramatically safer if constructed from materials that prevent clot formation and coagulation disturbance at the blood-biomaterial interface. Nitric oxide (NO), an endogenous inhibitor of platelet activation in the vascular endothelium, could provide anticoagulation at the blood-surface interface when applied to biomaterials. We investigated an application of a copper-based metal-organic framework, H3[(Cu4Cl)3(BTTri)8-(H2O)12]·72H2O where H3BTTri = 1,3,5-tris(1H-1,2,3-triazole-5-yl)benzene] (CuBTTri), which has been shown to be an effective catalyst to generate NO from S-nitrosothiols that are endogenously present in blood. A method was developed to apply a CuBTTri composite coating to Tygon medical tubing used for extracorporeal lung support devices. The stability and activity of the coating were evaluated during 72 h dynamic saline flow testing (1.5-2.5 L/min, n = 3) with scanning electron microscopy imaging and inductively coupled mass-spectroscopy analysis. Compatibility of the coating with whole blood was assessed with a panel of hemocompatibility tests during 6 h circulation of swine donor blood in an ex vivo circulation loop constructed with CuBTTri tubing or unmodified Tygon (1.5 L/min blood flow rate, n = 8/group). Thrombus deposition and catalytic activity of the CuBTTri tubing were assessed following blood exposure. The coating remained stable during 72 h saline flow experiments at clinically relevant flow rates. No adverse effects were observed relative to controls during blood compatibility testing, to include no significant changes in platelet count (p = 0.42), platelet activation indicated by P-selectin expression (p = 0.57), coagulation panel values, or methemoglobin fraction (p = 0.18) over the 6 h circulation period. CuBTTri within the coating generated NO following blood exposure in the presence of biologically relevant concentrations of an NO donor. CuBTTri composite coating was stable and blood compatible in this pilot study and requires further investigation of efficacy using in vivo models conducted with clinically relevant blood flow rates and study duration.Keywords
Funding Information
- Congressionally Directed Medical Research Programs (W81XWH-18-2-0048)
This publication has 36 references indexed in Scilit:
- A Tunable, Stable, and Bioactive MOF Catalyst for Generating a Localized Therapeutic from Endogenous SourcesAdvanced Functional Materials, 2014
- Invitro and in vivo study of sustained nitric oxide release coating using diazeniumdiolate-doped poly(vinyl chloride) matrix with poly(lactide-co-glycolide) additiveJournal of Materials Chemistry B, 2013
- Variability in Anticoagulation Management of Patients on Extracorporeal Membrane OxygenationPediatric Critical Care Medicine, 2013
- A phase I clinical study of inhaled nitric oxide in healthy adultsJournal of Cystic Fibrosis, 2012
- Routes for Formation of S-Nitrosothiols in BloodCell Biochemistry and Biophysics, 2011
- The hemocompatibility of a nitric oxide generating polymer that catalyzes S-nitrosothiol decomposition in an extracorporeal circulation modelBiomaterials, 2011
- Strong CO2 Binding in a Water-Stable, Triazolate-Bridged Metal−Organic Framework Functionalized with EthylenediamineJournal of the American Chemical Society, 2009
- Are Standard Human Coagulation Tests Suitable in Pigs and Calves During Extracorporeal Circulation?Artificial Organs, 2001
- The Biological and Pharmacological Role of Nitric Oxide in Platelet Function1993
- Measurements of Serum Levels of Nitrate Ions in Men and Women: Implications of Endothelium-Derived Relaxing Factor in Blood Pressure Regulation and AtherosclerosisJournal of Cardiovascular Pharmacology, 1992